positive
Recently
Aptus Pharma IPO Sees 4x Subscription Ahead of Listing
No Image
Aptus Pharma IPO subscribed 4x, GMP signals 10% listing gains.
Aptus Pharma’s SME IPO, priced in the ₹65–70 band, has drawn strong investor demand with subscriptions crossing 4x overall. Non-institutional and retail investors have shown heavy interest, while grey market premium indicates a potential 10% upside on listing. The issue, worth ₹48 crore, is scheduled to debut on September 30 on the BSE SME platform, adding momentum to the current wave of small-cap healthcare listings in India.